Faculty Profile

Dr. Amir Faisal

Associate Professor

Department Of Biology

Dr. Amir Faisal received his PhD in Cell Biology from Friedrich Miescher Institute for Biomedical Research/University of Basel, Switzerland in 2004. During his PhD he identified novel roles for Shc protein, an important adaptor downstream of tyrosine kinases, in insulin signalling and cytoskeletal reorganization. He received his first postdoctoral training (2004-2008) in Protein Phosphorylation Laboratory at London Research Institute where he discovered that another adaptor protein, MyD88, couples Protein Kinase C epsilon to Toll like receptors during innate immunity. From 2008 to 2014, he worked at Cancer Therapeutics Unit of Institute of Cancer Research in Sutton first as postdoctoral fellow and later as senior scientist. He played an important role in progression of several drug discovery projects, one of which resulted in discovery of a pre-clinical development candidate that will undergo phase I clinical trials in 2016. After joining LUMS in August 2014, he has been establishing a cancer therapeutics lab at SBASSE.

Title Publication Author Year
ATLANTIS - Attractor Landscape Analysis Toolbox for Cell Fate Discovery and Reprogramming Scientific Reports Shah O.S., Chaudhary M.F.A., Awan H.A., Fatima F., Arshad Z., Amina B., Ahmed M., Hameed H., Furqan M., Khalid S., Faisal A., Chaudhary S.U. 2018
Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistance Scientific Reports Manzoor S., Bilal A., Khan S., Ullah R., Iftikhar S., Emwas A.-H., Alazmi M., Gao X., Jawaid A., Saleem R.S.Z., Faisal A. 2018
Aurora B prevents premature removal of spindle assembly checkpoint proteins from the kinetochore: A key role for Aurora B in mitosis Oncotarget Gurden M.D., Anderhub S.J., Faisal A., Linardopoulos S. 2018
Nicotine exposure augments renal toxicity of 5-azacytidine through p66shc: Prevention by resveratrol Anticancer Research Arany I., Hall S., Faisal A., Dixit M. 2017
Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy British Journal of Cancer Faisal A., Mak G.W.Y., Gurden M.D., Xavier C.P.R., Anderhub S.J., Innocenti P., Westwood I.M., Naud S., Hayes A., Box G., Valenti M.R., De Haven Brandon A.K., O'Fee L., Schmitt J., Woodward H.L., Burke R., Vanmontfort R.L.M., Blagg J., Raynaud F.I., Eccles S.A., Hoelder S., Linardopoulos S. 2017
Natural products from Cuscuta reflexa Roxb. with antiproliferation activities in HCT116 colorectal cell lines Natural Product Research Riaz M., Bilal A., Ali M.S., Fatima I., Faisal A., Sherkheli M.A., Asghar A. 2017
Synthesis and evaluation of modified chalcone based p53 stabilizing agents Bioorganic and Medicinal Chemistry Letters Iftikhar S., Khan S., Bilal A., Manzoor S., Abdullah M., Emwas A.-H., Sioud S., Gao X., Chotana G.A., Faisal A., Saleem R.S.Z. 2017
Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach Journal of Medicinal Chemistry Innocenti P., Woodward H.L., Solanki S., Naud S., Westwood I.M., Cronin N., Hayes A., Roberts J., Henley A.T., Baker R., Faisal A., Mak G.W.-Y., Box G., Valenti M., De Haven Brandon A., O'Fee L., Saville H., Schmitt J., Matijssen B., Burke R., Van Montfort R.L.M., Raynaud F.I., Eccles S.A., Linardopoulos S., Blagg J., Hoelder S. 2016
7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent Bioorganic and Medicinal Chemistry Letters Bavetsias V., Perez-Fuertes Y., McIntyre P.J., Atrash B., Kosmopoulou M., O'Fee L., Burke R., Sun C., Faisal A., Bush K., Avery S., Henley A., Raynaud F.I., Linardopoulos S., Bayliss R., Blagg J. 2015
Naturally occurring mutations in the MPS1 gene predispose cells to kinase inhibitor drug resistance Cancer Research Gurden M.D., Westwood I.M., Faisal A., Naud S., Cheung K.-M.J., McAndrew C., Wood A., Schmitt J., Boxall K., Mak G., Workman P., Burke R., Hoelder S., Blagg J., Van Montfort R.L.M., Linardopoulos S. 2015
Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines Bioorganic and Medicinal Chemistry Letters Cheeseman M.D., Faisal A., Rayter S., Barbeau O.R., Kalusa A., Westlake M., Burke R., Swan M., Van Montfort R., Linardopoulos S., Jones K. 2014
Structure-based design of orally bioavailable 1 h -Pyrrolo[3,2- C ]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1) Journal of Medicinal Chemistry Naud S., Westwood I.M., Faisal A., Sheldrake P., Bavetsias V., Atrash B., Cheung K.-M.J., Liu M., Hayes A., Schmitt J., Wood A., Choi V., Boxall K., Mak G., Gurden M., Valenti M., De Haven Brandon A., Henley A., Baker R., McAndrew C., Matijssen B., Burke R., Hoelder S., Eccles S.A., Raynaud F.I., Linardopoulos S., Van Montfort R.L.M., Blagg J. 2013
Aurora isoform selectivity: Design and synthesis of imidazo[4,5- B ]pyridine derivatives as highly selective inhibitors of aurora-A kinase in cells Journal of Medicinal Chemistry Bavetsias V., Faisal A., Crumpler S., Brown N., Kosmopoulou M., Joshi A., Atrash B., Perez-Fuertes Y., Schmitt J.A., Boxall K.J., Burke R., Sun C., Avery S., Bush K., Henley A., Raynaud F.I., Workman P., Bayliss R., Linardopoulos S., Blagg J. 2013
Optimization of imidazo[4,5- b ]pyridine-based kinase inhibitors: Identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia Journal of Medicinal Chemistry Bavetsias V., Crumpler S., Sun C., Avery S., Atrash B., Faisal A., Moore A.S., Kosmopoulou M., Brown N., Sheldrake P.W., Bush K., Henley A., Box G., Valenti M., De Haven Brandon A., Raynaud F.I., Workman P., Eccles S.A., Bayliss R., Linardopoulos S., Blagg J. 2012
Selective FLT3 inhibition of FLT3-ITD+acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns Leukemia Moore A.S., Faisal A., De Castro D.G., Bavetsias V., Sun C., Atrash B., Valenti M., De Haven Brandon A., Avery S., Mair D., Mirabella F., Swansbury J., Pearson A.D.J., Workman P., Blagg J., Raynaud F.I., Eccles S.A., Linardopoulos S. 2012
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in Vivo Molecular Cancer Therapeutics Faisal A., Vaughan L., Bavetsias V., Sun C., Atrash B., Avery S., Jamin Y., Robinson S.P., Workman P., Blagg J., Raynaud F.I., Eccles S.A., Chesler L., Linardopoulos S. 2011
Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cells Cancer Letters Clark J.S., Faisal A., Baliga R., Nagamine Y., Arany I. 2010
Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells Bioorganic and Medicinal Chemistry Letters Bouloc N., Large J.M., Kosmopoulou M., Sun C., Faisal A., Matteucci M., Reynisson J., Brown N., Atrash B., Blagg J., McDonald E., Linardopoulos S., Bayliss R., Bavetsias V. 2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of aurora kinases: Lead optimization studies toward the identification of an orally bioavailable preclinical development candidate Journal of Medicinal Chemistry Bavetsias V., Large J.M., Sun C., Bouloc N., Kosmopoulou M., Matteucci M., Wilsher N.E., Martins V., Reynisson J., Atrash B., Faisal A., Urban F., Valenti M., De Haven Brandon A., Box G., Raynaud F.I., Workman P., Eccles S.A., Bayliss R., Blagg J., Linardopoulos S., McDonald E. 2010
p66SHC-mediated mitochondrial dysfunction in renal proximal tubule cells during oxidative injury American Journal of Physiology - Renal Physiology Arany I., Faisal A., Clark J.S., Vera T., Baliga R., Nagamine Y. 2010
A cancer-associated Aurora a mutant is mislocalized and misregulated due to loss of interaction with TPX2 Journal of Biological Chemistry Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R., Bayliss R., Linardopoulos S. 2009
The regulated assembly of a PKCe complex controls the completion of cytokinesis Nature Cell Biology Saurin A.T., Durgan J., Cameron A.J., Faisal A., Marber M.S., Parker P.J. 2008
The scaffold MyD88 acts to couple protein kinase C?? to toll-like receptors Journal of Biological Chemistry Faisal A., Saurin A., Gregory B., Foxwell B., Parker P.J. 2008
p66shc inhibits pro-survival epidermal growth factor receptor/ERK signaling during severe oxidative stress in mouse renal proximal tubule cells Journal of Biological Chemistry Arany I., Faisal A., Nagamine Y., Safirstein R.L. 2008
Protein kinases, from B to C Biochemical Society Transactions Cameron A.J., De Rycker M., Calleja V., Alcor D., Kjaer S., Kostelecky B., Saurin A., Faisal A., Laguerre M., Hemmings B.A., McDonald N., Larijani B., Parker P.J. 2007